Covid-19, multi-drug resistant bacteria and other public health issues are poised to change key aspects of the global healthcare industry and escalate the importance of innovation in prevention, diagnosis of treatment of infectious diseases.

Health Advances partners with infectious disease innovators across life science sectors to bring novel infectious disease technologies to market, by providing actionable insights and strategies that enable critical business decisions.

Over more than 28 years, Health Advances has built a strong understanding of the unique dynamics that affect the commercialization of infectious disease technologies with unparalleled depth of insight into the complexities of each technology and disease indication. Our team of scientists, physicians, and industry experts are thought leaders in identifying and analyzing the unmet needs in a variety of infectious disease areas and developing strategies to address those opportunities. We combine decades of experience in new technology commercialization across healthcare segments – diagnostics and life science tools, biopharma, medtech, health IT and digital health, and healthcare services – with an unmatched understanding of international health systems and policies to deliver impactful strategies across global markets.

For more information on Health Advances’ expertise and specific capabilities in infectious disease, please contact our team at

For Health Advances’ thought leadership on the evolving market landscape in the face of COVID-19, please see Health Advances’ blog series.

Read our Diagnostics Practice’s report on Demystifying COVID Testing.

Read our brochure for Infectious Disease case examples.